These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 6223824)

  • 1. Normal and low molecular weight heparins: interaction with human platelets.
    Fabris F; Fussi F; Casonato A; Visentin L; Randi M; Smith MR; Girolami A
    Eur J Clin Invest; 1983 Apr; 13(2):135-9. PubMed ID: 6223824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects on platelets and on the clotting system of four glycosaminoglycans extracted from hog mucosa and one extracted from aortic intima of the calf.
    Cella G; Scattolo N; Luzzatto G; Stevanato F; Vio C; Girolami A
    J Med; 1986; 17(5-6):331-46. PubMed ID: 2953835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of low-molecular-weight heparin on platelets as compared with commercial heparin.
    Cella G; Scattolo N; Luzzatto G; Girolami A
    Res Exp Med (Berl); 1984; 184(4):227-9. PubMed ID: 6494594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulant effects of a low molecular weight heparinoid (Org 10172) in human volunteers and haemodialysis patients.
    ten Cate H; Henny CP; ten Cate JW; Büller HR; Mooy MC; Surachno S; Wilmink JM
    Thromb Res; 1985 Jul; 39(2):211-22. PubMed ID: 3161213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms for the anticoagulant effect of heparin and related polysaccharides.
    Ofosu FA
    Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls.
    Burgess JK; Chong BH
    Eur J Haematol; 1997 Apr; 58(4):279-85. PubMed ID: 9186540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of dermatan sulfate on in vitro human plasma coagulation, platelet aggregation and beta TG/PF4 release.
    Cofrancesco E; Colombi M; Gianese F; Cortellaro M
    Thromb Res; 1990 Feb; 57(3):405-14. PubMed ID: 2138364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways.
    Ofosu FA; Modi GJ; Smith LM; Cerskus AL; Hirsh J; Blajchman MA
    Blood; 1984 Sep; 64(3):742-7. PubMed ID: 6235872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of heparinoids with platelets: comparison with heparin and low molecular weight heparins.
    Messmore HL; Griffin B; Koza M; Seghatchian J; Fareed J; Coyne E
    Semin Thromb Hemost; 1991; 17 Suppl 1():57-9. PubMed ID: 1712512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anticoagulant effect of heparan sulfate and dermatan sulfate.
    Teien AN; Abildgaard U; Höök M
    Thromb Res; 1976 Jun; 8(6):859-67. PubMed ID: 134464
    [No Abstract]   [Full Text] [Related]  

  • 11. Heparin-induced platelet aggregation in anorexia nervosa and in severe peripheral vascular disease.
    Mikhailidis DP; Barradas MA; Jeremy JY; Gracey L; Wakeling A; Dandona P
    Eur J Clin Invest; 1985 Dec; 15(6):313-9. PubMed ID: 3938401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dermatan sulfate and heparan sulfate on platelet activity compared to heparin.
    Hoppensteadt DA; Walenga JM; Fareed J
    Semin Thromb Hemost; 1991; 17 Suppl 1():60-4. PubMed ID: 2068572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of glycosaminoglycans and protamine chloridrate on platelet aggregation induced by collagen and thrombin.
    Luzzatto G; Paolini R; Stevanato F; Simioni P; Cella G
    Angiology; 1989 Mar; 40(3):170-4. PubMed ID: 2916768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets.
    Messmore HL; Griffin B; Fareed J; Coyne E; Seghatchian J
    Ann N Y Acad Sci; 1989; 556():217-32. PubMed ID: 2472085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate.
    Ofosu FA; Modi GJ; Blajchman MA; Buchanan MR; Johnson EA
    Biochem J; 1987 Dec; 248(3):889-96. PubMed ID: 2963622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet activation following intravenous injection of a conventional heparin: absence of effect with a low molecular weight heparinoid (Org 10172).
    Mikhailidis DP; Fonseca VA; Barradas MA; Jeremy JY; Dandona P
    Br J Clin Pharmacol; 1987 Oct; 24(4):415-24. PubMed ID: 3689624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impairment of primary haemostasis by low molecular weight heparins in rats.
    Borowska A; Lauri D; Maggi A; Dejana E; de Gaetano G; Donati MB; Pangrazzi J
    Br J Haematol; 1988 Mar; 68(3):339-44. PubMed ID: 3355792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models.
    Meuleman DG; Hobbelen PM; van Dedem G; Moelker HC
    Thromb Res; 1982 Aug; 27(3):353-63. PubMed ID: 6182627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of glycosaminoglycans on U-937 leukemia cell proliferation and differentiation: structure-function relationship.
    Volpi N; Petrini M; Conte A; Valentini P; Venturelli T; Bolognani L; Ronca G
    Exp Cell Res; 1994 Nov; 215(1):119-30. PubMed ID: 7957660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of low molecular weight heparin in clinical laboratory.
    van Putten J; van de Ruit M; Beunis M; Hemker HC
    Haemostasis; 1984; 14(2):205-10. PubMed ID: 6203817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.